SYBX — Synlogic, Inc.

Summary of Synlogic's Q2 2022 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $0.2 million for Q2 2022, consistent with Q2 2021, primarily from a collaboration with Roche.
• Net Loss: $15.7 million for Q2 2022, slightly higher than the $15 million loss in Q2 2021.
• Cash Position: Ended Q2 2022 with $106.8 million in cash, cash equivalents, and marketable securities, down from $120.5 million at the end of Q1 2022. The company expects this cash to support operations into 2024.

2. Strategic Updates and Business Highlights

• Clinical Progress:
  • Received a positive opinion for orphan drug designation from the EMA for SYNB 1618, targeting phenylketonuria (PKU).
  • Anticipates three clinical data readouts in the latter half of 2022, including Phase II data for SYNB 1618 and findings from SYNB 1353 (for homocystinuria) and SYNB 8802 (for enteric hyperoxaluria).
  • Launched SYNB 2081 for gout, developed in partnership with Ginkgo Bioworks.
• Pipeline Development: SYNB 1353 entered the clinic within a year of candidate designation, showcasing the efficiency of Synlogic's synthetic biotic platform.

3. Forward Guidance and Outlook

• Phase III Study: Planning to initiate a Phase III study for SYNB 1618 in PKU in the first half of 2023, with trial readiness activities underway.
• Data Readouts: Expecting significant clinical data readouts in the coming months, which could validate the efficacy of their synthetic biotic therapies.

4. Bad News, Challenges, or Points of Concern

• Market Dynamics: Concerns were raised regarding the recovery of PKU treatment centers post-pandemic, which could impact enrollment rates. However, management remains optimistic about the demand for new therapies.
• Enrollment Challenges: The company is aware of potential difficulties in enrolling patients for the Phase III trial compared to Phase II, although they plan to mitigate this through a broader geographic reach and less intensive study design.
• Competitive Pressures: Other companies in the PKU space have adjusted sales guidance, indicating a challenging market environment that Synlogic is monitoring closely.

5. Notable Q&A Insights

• Enrollment Expectations: Management expects the Phase III enrollment to be facilitated by more sites and a less burdensome design compared to Phase II, which involved intensive data collection.
• Pediatric Development: Plans to include pediatric patients in future studies, with considerations for different endpoints based on age-related responses.
• Manufacturing Capabilities: The company has made significant progress in manufacturing capabilities to support Phase III, with positive feedback from the FDA on CMC requirements.
• Gout Program Insights: Discussion on SYNB 2081 indicated potential effects on both dietary and endogenous uric acid production, highlighting the complexity of uric acid metabolism.

Overall, Synlogic is positioned for a busy second half of 2022 with multiple data readouts and a focus on advancing its clinical programs, despite facing market challenges and competitive pressures in the PKU treatment landscape.